Inovio and The Wistar Institute Receive More Than $4.6 Million in R&D Funding

Inovio Pharmaceuticals (NASDAQ:INO) announced that the company is collaborating with The Wistar Institute to advance two novel SynCon^® vaccine programs against tuberculosis and malaria, fully funded by more than $4.6 million in total grants from the Bill & Melinda Gates Foundation and the National Institutes of Health.

As quoted in the press release:

Grants from the Gates Foundation (for malaria) and from the National Institute of Allergy & Infectious Diseases (for TB) will fully support Inovio’s efforts to develop new DNA vaccines employing its versatile ASPIRE (Antigen SPecific Immune REsponses) platform that is leading the way forward for activation immunotherapy. This one-of-a-kind platform delivers optimized synthetic antigenic genes into cells, where it is translated into protein antigens that activate an individual’s immune system to generate robust targeted T cell and antibody responses.

Click here to read the full press release.